A major cyberattack, attributed to an Iran-linked group, has disrupted Stryker's global operations, wiping devices and halting production. The incident raises urgent questions about supply chain resilience for hospitals and tests the medical device giant's digital growth strategy amid increasing regulatory scrutiny.
Medical device giant Stryker reports significant progress in restoring its global manufacturing and ordering systems after a disruptive cyberattack earlier this month, which an Iran-affiliated group claimed as retaliation.
A single Reddit post alleging a major cyberattack by an Iranian-linked group sparked a 9% sell-off in Stryker shares last week, despite the medical device giant reporting record revenue and robust growth. Analysts point to a disconnect between online speculation and the company's solid financial health.
The Iran-linked 'Handala' hacking group has claimed responsibility for a major cyberattack on U.S. medical technology firm Stryker, crippling its global network in what it calls retaliation for recent strikes.
Stryker's Mako RPS handheld surgical robot enters a controlled market release, targeting surgeons who prefer manual techniques, as the company details its phased launch strategy and showcases new knee implant technology at the annual orthopedic conference.
Medical technology giant Stryker Corporation has declared a quarterly cash dividend, continuing its long-standing shareholder return policy. While the yield sits below some industry peers, strong earnings coverage and a robust growth forecast underpin the payout's stability.
Stryker has initiated a limited market release of its new Mako RPS handheld robotic system for total knee replacements. The device targets surgeons seeking robotic precision without the complexity of larger platforms, potentially expanding access to robotic-assisted procedures.
Medical device giant Stryker announces a 4.8% increase to its quarterly dividend, a move analysts interpret as a vote of confidence in the company's sustained cash generation and earnings stability amidst a mixed recent stock performance.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
Medical technology giant Stryker faces a critical test as it works to recover from a major March 2026 cyberattack that crippled global operations. The incident casts a shadow over, yet simultaneously underscores the urgency of, its aggressive push into digital health with its SmartHospital platform and expanded robotic surgery portfolios.
Medical device giant Stryker is working to restore its systems after a cyberattack claimed by an Iran-linked group disrupted its global order processing, manufacturing, and shipping. The company assures patient care services remain unaffected.
The global operations of medical device manufacturer Stryker were disrupted by a cyberattack claimed by the Iran-linked Handala group. The hackers cite retaliation for a recent deadly strike as they announce the theft of 50 terabytes of data and warn of a new phase in cyber warfare against Western interests.
Citigroup issued a series of research notes on major medical device companies, upgrading Intuitive Surgical to Buy and adjusting views on Stryker and Abbott. The bank argues that strong sector fundamentals are being overshadowed by broad market fear, creating selective opportunities for investors.
Investment firm UBS has increased its price target for Stryker Corporation (SYK) to $400, reflecting confidence in the medical technology giant's sustained financial strength and strategic positioning, even as it maintains a Neutral rating on the stock.
Despite trailing the S&P 500 over the past year, medical device leader Stryker is drawing cautious optimism from Wall Street following solid Q4 results, though analyst sentiment has softened slightly from earlier highs.
While Stryker's latest quarterly report appeared uneventful to some investors, a deeper look reveals potential for profit growth as one-off charges fade, with shares holding steady amidst a nuanced financial landscape.
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.
Medical technology giant Stryker is working to restore customer-facing systems after containing a disruptive cyberattack claimed by the Iran-affiliated Handala group, which cited retaliation for a strike in Iran. The company confirms no patient data or connected medical devices were compromised.
The medtech giant Stryker continues to navigate significant operational disruptions following a cyberattack claimed by an Iran-aligned group, raising concerns over global supply chains for critical surgical and orthopedic devices.
